GGrantIndex
Sort

21,281 grants matching influenza

Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacy

$725,288
Pamela Tinmoi Wong · University Of Michigan At Ann Arbor · R01 · FY2023 · AI

Genetic Markers of Long-Term Mumps Vaccine Immunity

$725,120
Richard B Kennedy · Mayo Clinic Rochester · R01 · FY2018 · AI

Case-Cohort Study of Cancers in Excess in Poultry Workers

$724,987
Eric S. Johnson · Univ Of Arkansas For Med Scis · R01 · FY2011 · OH

Case-Cohort Study of Cancers in Excess in Poultry Workers

$724,920
Eric S. Johnson · Univ Of Arkansas For Med Scis · R01 · FY2013 · OH

Case-Cohort Study of Cancers in Excess in Poultry Workers

$724,909
Eric S. Johnson · Univ Of Arkansas For Med Scis · R01 · FY2014 · OH

Effects of aging on primary and secondary vaccine responses in a 15-year longitudinal cohort

$724,766
Scott Dexter Boyd · Stanford University · R01 · FY2019 · AI

Microneedle-based immunization against pandemic influenza

$724,647
Mark R Prausnitz · Georgia Institute Of Technology · R01 · FY2007 · EB

HMGB1-mediated host response to chronic bacterial infection

$724,279
Steven D Goodman · Research Inst Nationwide Children'S Hosp · R01 · FY2021 · AI

Neisserial porins and antigen presenting cells

$724,093
Lee Mark Wetzler · Boston Medical Center · R01 · FY2016 · AI

Case-Cohort Study of Cancers in Excess in Poultry Workers

$724,063
Eric S. Johnson · Univ Of Arkansas For Med Scis · R01 · FY2015 · OH

Improving predictive capacity of models for universal influenza vaccine development

$723,996
Richard John Webby · St. Jude Children'S Research Hospital · R01 · FY2020 · AI

Vervet Research Colony as a Biomedical Resource

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2023 · OD

Component for Institution # 19-01414

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2024 · OD

Component for Institution # 19-01414

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2021 · OD

Vervet Research Colony as a Biomedical Resource

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2022 · OD

Component for Institution # 19-01414

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2023 · OD

Vervet Research Colony as a Biomedical Resource

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2024 · OD

Vervet Research Colony as a Biomedical Resource

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2020 · OD

Vervet Research Colony as a Biomedical Resource

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2021 · OD

Component for Institution # 19-01414

$723,833
Matthew Jorgensen · Wake Forest University Health Sciences · P40 · FY2020 · OD

Mitochondrial maladaptive response of the lung epithelium to elevated CO2 levels

$723,736
Jacob I Sznajder · Northwestern University At Chicago · R01 · FY2024 · HL

Mitochondrial maladaptive response of the lung epithelium to elevated CO2 levels

$723,736
Jacob I Sznajder · Northwestern University At Chicago · R01 · FY2025 · HL

De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics

$723,634
David Baker · University Of Washington · R01 · FY2021 · AI

Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Cell Transplant Recipients

$723,553
Guang-Shing Cheng · Fred Hutchinson Cancer Center · R01 · FY2022 · HL

mRNA-encoded Cas13 as a pan-respiratory antiviral

$723,501
Philip J Santangelo · Emory University · R01 · FY2023 · AI